<DOC>
	<DOCNO>NCT01697306</DOCNO>
	<brief_summary>To knowledge , comparative study bacillus Calmette-Guerin ( BCG ) intravesical chemotherapy address quality life ( QoL ) issue . The aim study prospectively evaluate compare QoL intermediate-risk non-muscle-invasive ( NMIBC ) patient treat BCG gemcitabine .</brief_summary>
	<brief_title>The Impact Intravesical Gemcitabine 1/3 Dose Bacillus Calmette-Guerin Quality Life Superficial Bladder Cancer</brief_title>
	<detailed_description>Intravesical Bacillus Calmette-Guérin ( BCG ) consider effective agent non-muscle-invasive bladder cancer ( NMIBC ) , represent first-line option management carcinoma situ ( CIS ) high-risk disease . In intermediate-risk NMIBC , however , BCG intravesical chemotherapy accept alternative adjuvant option since superiority BCG establish disease recurrence progression need balance high toxicity . According current evidence , BCG consider less tolerable intravesical chemotherapy mitomycin-C doxorubicin , base report side effect . Among chemotherapeutic agent , gemcitabine excellent toxicity profile promise efficacy NMIBC patient , include high-risk disease recurrence , even role management NMIBC well-defined yet . To knowledge , comparative study BCG intravesical chemotherapy address quality life ( QoL ) issue . The aim study prospectively evaluate compare QoL intermediate-risk NMIBC patient treat BCG gemcitabine .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>patient clinical evidence intermediaterisk nonmuscle invasive bladder cancer ( namely Ta1 , G12 , multifocal unique recurrent , &gt; 3 cm diameter ) WHO performance status ≤2 age ≤85years BCG naive patient treat intravesical chemotherapy last 3 month . presence T1G3 CIS preoperative urinary cytology positive highgrade atypia inadequate bone marrow reserve ( white blood cell &lt; 3 x 109/l , platelet &lt; 100 x 109/l ) history genitourinary tuberculosis presence uncontrolled urinary infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>non muscle invasive bladder cancer</keyword>
</DOC>